Krill OilKOMMNCT07130513
Investigating the Feasibility of Krill Oil Intervention to Improve Muscle Function in Adults With Long-term Conditions
A study testing Krill oil supplementation in people with Krill Oil and Muscle Function, run by University of Glasgow at 2 sites in United Kingdom.
Trial summary
This study will recruit 30 adults (men and women, aged 18 years and over) who will be randomly assigned to one of two groups in a 12-week double-blind pilot trial. Participants will receive either: Arm 1: Krill Oil group: 4 g/day of krill oil supplements (Superba™ Antarctic Krill Oil, 1000 mg capsules), or Arm 2… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Krill Oil, Muscle Function, Grip Strength
- What is being tested?
- Krill oil supplementation
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 18 Aug 2025to 30 Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men and women aged ≥18 years who are in the high-risk long-term condition group (having one or more LTCs, including rheumatoid arthritis, gout, type 2 diabetes, coronary heart disease, and stroke [including transient ischemic attack, TIA]).
Who cannot join
- Participants are diagnosed with and being treated for any type of cancer.
- Presence of neurocognitive disorders or any health condition affecting memory (e.g., Alzheimer's disease, dementia).
- Aortic stenosis, history of haemorrhagic stroke, or presence of aneurysms.
- Current anticoagulant therapy.
- Use of any muscle mass supplements or presence of physiological conditions such as pregnancy or breastfeeding.
- History of allergy to fish or fish oil.
- Regular consumption of more than one portion of oily fish per week, or use of fish oil or krill oil supplements.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom2 sites, 2 recruiting
- Recruiting
Lab 242, Sir James Black Building, University of Glasgow
Glasgow, Lanarkshire, G12 8TA
Marion Guerrero, 07922634654, marion.g.wyss@gmail.com
Lynsey Johnston, 01413306287, Lynsey.Johnston@glasgow.ac.uk
- Not yet recruiting
University of Glasgow
Glasgow, Lanarkshire, G12 8TA
Stuart Gray, 01413302569, stuart.gray@glasgow.ac.uk
About this study
Official title: The Effect of Krill Oil Supplementation on Muscle Function in Adults With High-risk Long-term Conditions: a Randomized Controlled Pilot Study.
This study will recruit 30 adults (men and women, aged 18 years and over) who will be randomly assigned to one of two groups in a 12-week double-blind pilot trial. Participants will receive either:
- Arm 1: Krill Oil group: 4 g/day of krill oil supplements (Superba™ Antarctic Krill Oil, 1000 mg capsules), or
- Arm 2: Control group: 4 g/day of placebo (vegetable oil capsules).
Read more
Participants will be instructed to maintain their usual diet and physical activity patterns throughout the study.
Eligibility will be assessed using a health screening questionnaire, completed with the researcher's assistance, before obtaining informed consent. Habitual physical activity will be evaluated using the International Physical Activity Questionnaire (short form), and dietary intake will be assessed with the EPIC Food Frequency Questionnaire (FFQ) at both the beginning and end of the study. In addition, participants will record their fish consumption weekly using a dedicated logbook.
Measurements will be taken at baseline and after 12 weeks, including:
- Blood samples to assess inflammatory and metabolic markers.
- Anthropometry and body composition, including weight, height, fat mass, fat percentage, and muscle mass (via ultrasound).
- Muscle strength, measured using handgrip strength and maximal voluntary contraction (each performed three times with rest between attempts).
- Physical performance, assessed with a 4-meter walk test at normal speed Upon completing the study, participants will receive a £50 voucher in appreciation of their contribution.
- Being tested
- Krill oil supplementation, Control
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Krill oil supplementationDietary supplement
Also called Omega 3 supplementation
Krill oil supplementation program providing 4 g/day of krill oil (Superba™ Antarctic Krill Oil, 1000 mg capsules) for 12 weeks.
ControlDietary supplement
Vegetable oil supplementation (4 g/day)
| Study group | Role | What they receive |
|---|---|---|
| Arm 1: Krill Oil group | Experimental | 4 g/day of krill oil (Superba™ Antarctic Krill Oil, 1000 mg capsules) for 12 weeks. Receives: Dietary Supplement: Krill oil supplementation |
| Arm 2: Control group | Placebo comparator | 4 g/day of placebo (vegetable oil capsules) for 12 weeks. Receives: Dietary Supplement: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Grip strength
Measured using a handgrip dynamometer
Measured: Changes from baseline to week 12
Secondary outcomes (11)
Knee extendor Strength
Knee extensor maximal torque measured during an isometric maximal voluntary contraction (MVC)
Measured: Changes from baseline to week 12
Muscle size, assessed as vastus lateralis muscle thickness by ultrasound
The investigators will assess vastus lateralis muscle thickness using B-mode ultrasound, with participants in a supine position. This measurement will also serve as an indirect indicator of muscle damage through cell swelling. The measurement site will be located at 10% of the thigh circumference lateral to the midpoint between the iliac crest and the superior border of the patella.
Measured: Changes from baseline to week 12
Gait speed
Gait speed will be assessed as a measure of physical function.
Measured: From baseline to week 12
Fatty Acid Composition
A venous blood sample (15 ml) will be collected from an antecubital vein by a trained member of the research team and analysed for erythrocyte fatty acid profile.
Measured: From baseline to week 12
Inflammatory and metabolic markers
A venous blood sample (15 ml) will be collected by a trained member of the research team from an antecubital vein and analysed to estimate plasma glucose, lipids (triacylglycerol, total cholesterol, HDL), and markers of inflammation (e.g., hsCRP, IL-6, TNF-α, homocysteine).
Measured: From baseline to week 12
Height
Height recorded using a stadiometer in centimetre at the beginning of the study.
Measured: Changes from baseline to week 12
Bodyweight
Changes in bodyweight, recorded in kilogram. Measured via body composition analyser.
Measured: Changes from baseline to week 12
Body Mass Index (BMI)
Will be calculated from the bodyweight (in kilogram) and height (in meter) according to the BMI formula (kg/m^2).
Measured: Changes from baseline to week 12
Body Fat Mass
Changes in body fat mass, recorded in kilogram. Measured via body composition analyser.
Measured: Changes from baseline to week 12
Body Fat Percentages
Changes in body fat percentage, recorded in percentage. Measured via body composition analyser.
Measured: Changes from baseline to week 12
Fat Free Mass
Changes in fat free mass, recorded in kilogram. Measured via body composition analyser.
Measured: Changes from baseline to week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2025
- Study start18 Aug 2025
- Primary completion30 Jul 2026 (estimated)
- Study completion30 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Krill OilStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Glasgow
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Stuart Gray, University of Glasgow
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07130513
- Sponsor's protocol ID
- KOMM
- Acronym
- KOMM
- Status last verified
- Oct 2025
- First submitted
- 4 Aug 2025
- Last updated
- 2 Oct 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Krill Oil Supplementation on Muscle Function in Adults With High-risk Long-term Conditions: a Randomized Controlled Pilot Study.
- ClinicalTrials.gov ID
- NCT07130513
- Acronym / sponsor ID
- KOMM / KOMM
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- University of GlasgowUniversity, hospital or other
- Study start
- 18 Aug 2025 (actual)
- Primary completion
- 30 Jul 2026 (estimated)
- Study completion
- 30 Jul 2026 (estimated)
- First posted
- 19 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will recruit 30 adults (men and women, aged 18 years and over) who will be randomly assigned to one of two groups in a 12-week double-blind pilot trial. Participants will receive either:
- Arm 1: Krill Oil group: 4 g/day of krill oil supplements (Superba™ Antarctic Krill Oil, 1000 mg capsules), or
- Arm 2: Control group: 4 g/day of placebo (vegetable oil capsules).
Participants will be instructed to maintain their usual diet and physical activity patterns throughout the study.
Eligibility will be assessed using a health screening questionnaire, completed with the researcher's assistance, before obtaining informed consent. Habitual physical activity will be evaluated using the International Physical Activity Questionnaire (short form), and dietary intake will be assessed with the EPIC Food Frequency Questionnaire (FFQ) at both the beginning and end of the study. In addition, participants will record their fish consumption weekly using a dedicated logbook.
Measurements will be taken at baseline and after 12 weeks, including:
- Blood samples to assess inflammatory and metabolic markers.
- Anthropometry and body composition, including weight, height, fat mass, fat percentage, and muscle mass (via ultrasound).
- Muscle strength, measured using handgrip strength and maximal voluntary contraction (each performed three times with rest between attempts).
- Physical performance, assessed with a 4-meter walk test at normal speed Upon completing the study, participants will receive a £50 voucher in appreciation of their contribution.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm 1: Krill Oil group | Experimental | Dietary Supplement: Krill oil supplementation4 g/day of krill oil (Superba™ Antarctic Krill Oil, 1000 mg capsules) for 12 weeks. |
| Arm 2: Control group | Placebo comparator | Dietary Supplement: Control4 g/day of placebo (vegetable oil capsules) for 12 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Men and women aged ≥18 years who are in the high-risk long-term condition group (having one or more LTCs, including rheumatoid arthritis, gout, type 2 diabetes, coronary heart disease, and stroke [including transient ischemic attack, TIA]).
Key exclusion criteria (7 listed)
- Participants are diagnosed with and being treated for any type of cancer.
- Presence of neurocognitive disorders or any health condition affecting memory (e.g., Alzheimer's disease, dementia).
- Aortic stenosis, history of haemorrhagic stroke, or presence of aneurysms.
- Current anticoagulant therapy.
- Use of any muscle mass supplements or presence of physiological conditions such as pregnancy or breastfeeding.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Krill oil supplementationAlso: Omega 3 supplementationKrill oil supplementation program providing 4 g/day of krill oil (Superba™ Antarctic Krill Oil, 1000 mg capsules) for 12 weeks. | Dietary supplement | Arm 1: Krill Oil group |
| ControlVegetable oil supplementation (4 g/day) | Dietary supplement | Arm 2: Control group |
Primary outcome
Grip strength
Time frame: Changes from baseline to week 12
Measured using a handgrip dynamometer
11 secondary outcomes
Knee extendor Strength
Time frame: Changes from baseline to week 12
Muscle size, assessed as vastus lateralis muscle thickness by ultrasound
Time frame: Changes from baseline to week 12
Gait speed
Time frame: From baseline to week 12
Fatty Acid Composition
Time frame: From baseline to week 12
Inflammatory and metabolic markers
Time frame: From baseline to week 12
Height
Time frame: Changes from baseline to week 12
Bodyweight
Time frame: Changes from baseline to week 12
Body Mass Index (BMI)
Time frame: Changes from baseline to week 12
Body Fat Mass
Time frame: Changes from baseline to week 12
Body Fat Percentages
Time frame: Changes from baseline to week 12
Fat Free Mass
Time frame: Changes from baseline to week 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2025.
- Individual participant dataSharing planned: No
Related trials for Krill Oil
Recruiting
Investigating the Effects of Krill Oil on the Recovery From Muscle Damaging Exercise: a Randomised Controlled Trial
Looking at the Effects of Krill Oil Supplementation on Recovery From Muscle-damaging Exercise
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Krill oil supplementation in people with Krill Oil and Muscle Function, run by University of Glasgow at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Professor Stuart Gray (+441413302569, stuart.gray@glasgow.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Grip strength (time frame: Changes from baseline to week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2025; AzTrials last refreshed its copy on 8 Nov 2026.